Skip to main content
Erschienen in: Journal of Medical Case Reports 1/2022

Open Access 01.12.2022 | Case report

Vascular thromboses with retroperitoneal fibrosis: a case report

verfasst von: Hanane Charaf, Rachida Zahraoui, Mouna Soualhi, Nezha Rguig, Jamal Eddine Bourkadi, Daoud Ali Mohamed, Nasser Ittimad

Erschienen in: Journal of Medical Case Reports | Ausgabe 1/2022

Abstract

Background

Granulomatosis with polyangiitis is a systemic inflammatory disease characterized by necrotizing vasculitis that affects small- and medium-sized blood vessels. Granulomatous inflammation affects the lungs, ears, nose, and throat, and commonly affects the kidneys, although the retroperitoneal tissue is rarely affected. Several studies have reported an increased risk of venous thromboembolism. Early diagnosis and treatment are of vital importance due to the rapid progression of the disease.

Case presentation

We present the case of a 66-year-old Moroccan man followed for bilateral jugular thrombosis. Cavitary pulmonary nodules and retroperitoneal fibrosis with thrombosis involving several vascular territories were detected on thoracoabdominopelvic computerized tomography scan. Laboratory analyses revealed that the patient was positive for cytoplasmic antineutrophilic antibodies. The diagnosis of granulomatosis with polyangiitis was retained. Treatment with glucocorticoids and immunosuppressive agents resulted in significant clinical and radiological improvement over the following months.

Conclusions

We describe the diagnostic steps and the difficulty of managing this patient. Rare manifestations, such as retroperitoneal fibrosis, have been reported in the literature in association with granulomatosis with polyangiitis, and should not delay the diagnosis and treatment of granulomatosis with polyangiitis owing to its severity.
Hinweise

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Abkürzungen
GPA
Granulomatosis with polyangiitis
ENT
Ears, nose, throat
VTE
Venous thromboembolism
c-ANCA
Cytoplasmic antineutrophilic antibodies
PE
Pulmonary embolism
DVT
Deep venous thrombosis
AAV
Cytoplasmic antineutrophilic antibodies-associated vasculitis
HR
Hazard ratio
CI
Confidence interval
CRP
C-reactive protein
WGET
Wegener’s granulomatosis etanercept trial
EGPA
Eosinophilic granulomatosis with polyangiitis
MPA
Microscopic polyangiitis
WG
Wegener granulomatosis
RPF
Retroperitoneal fibrosis
CT-scan
Computed tomography scan

Introduction

Granulomatosis with polyangiitis (GPA) is a necrotizing vasculitis affecting predominantly small to medium vessels (capillaries, venules, arterioles, arteries, and veins) [1]. This condition was previously known as Wegener’s granulomatosis. It is a rare disease, with an incidence in Europe of 2.1–14.4 cases/million, and it occurs in all age groups [2]. An increased incidence of various vascular events was demonstrated among GPA patients. We have shown that GPA patients are at increased risk of hospitalization for ischemic heart disease manifestations compared with age- and sex-matched controls [3]. For venous thromboembolic events (VTE), Merkel et al. reported a high occurrence of pulmonary embolism (PE) and deep venous thrombosis (DVT) among GPA patients included in a randomized therapeutic trial [4]. Among the observed VTEs, 81% occurred in patients with active or recently active vasculitis. Alvise Berti et al. found that, for patients with cytoplasmic antineutrophilic antibodies (ANCA)-associated vasculitis (AAV), the hazard ratio (HR) for venous thromboembolism VTE was 3.26 [95% confidence interval (CI) 0.84–12.60] and significantly increased for peripheral vascular disease DVT (HR 6.25, 95% CI 1.16–33.60), but not for pulmonary embolism (PE; HR 1.33, 95% CI 0.23–7.54) [5]. Other structures such as the retroperitoneal tissue, or large vessels including the aorta, are rarely involved. Retroperitoneal fibrosis incidence is 0.1 per 100,000 population/year with a prevalence of 1.4 per 100,000 population. Seventy percent of cases are idiopathic [2].
We present a case of multiple vascular thromboses, revealing granulomatous polyangiitis associated with retroperitoneal fibrosis without periaortitis. The association of retroperitoneal fibrosis with c-ANCA or p-ANCA positive systemic vasculitis is described in the literature, not only for granulomatosis with polyangiitis but also in other vasculitides such as Churg–Strauss syndrome [2].
The diagnosis of this association is lengthy and costly, with a lot of exploration [positron emission tomography (PET) scan and anatomopathological analysis of biopsies], which causes a delay in diagnosis that can expose the patient to complication risk [2, 3, 5].
Our observation describes the diagnostic particularity and management of this association, and we insist that retroperitoneal fibrosis should not delay the diagnosis of GPA or defer its therapeutic management.

Case description

The 66-year-old Moroccan male patient had a cumulative smoking index of 30 pack-years. The patient stopped smoking 5 years earlier, had no alcoholism, and had no personal or family history or professional or environmental exposure for bilateral jugular thrombosis. He was put on antivitamin K for 1 month and still developed thoracic pains with productive coughing bringing up hemoptoic sputum, lumbago, dysphonia, epistaxis, and deafness of the left ear of acute installation. At admission, the patient was respiratorily and hemodynamically stable. The general examination on admission revealed a conscious patient with good orientation in time and space, with a heart rate of 63 beats per minute, blood pressure of 120/60 mm Hg, respiratory rate of 16 breaths per minute, and temperature of 37 °C. On neurological examination, mobility, sensitivity, and osteotendinous reflexes were preserved. Examination of the cranial nerves was without anomalies. The rest of the physical examination was unremarkable except for red eyes and some leg purpuric lesions (Table 1). There were no peripheral signs of heart failure and no signs of peritoneal irritation on percussion, and chest X-ray showed several excavated opacities (Fig. 1). The thoracoabdominopelvic computed tomography scan revealed multiple thromboses, particularly in the jugular veins (Fig. 2), extended to the brachiocephalic trunk and the superior vena cava, and in the left common femoral vein, a left intraventricular thrombus. The sinus scan revealed chronic maxillary sinusitis with episcleritis perforation of its medial wall (Fig. 3), excavated bilateral nodular pulmonary lesions (Fig. 4) associated with a periaortic adenopathy flow, and a fly sheathing the aorta suggestive of retroperitoneal fibrosis (Fig. 5).The routine blood and urine analysis detected anemia. Renal and hepatic function were normal, and hepatitis B and C and human immunodeficiency virus (HIV) serologies were negative. There was an increase of the acute phase reactant C-reactive protein (CRP) 188 mg/L (normal value ≤ 6 mg/L), an increase of 24-hour proteinuria to 1.4 g/L (normal value 0.3 g/L), microscopic hematuria detected on cytobacteriological examination of urine, urinary sediment positive for blood and albumin, acid–alcohol resistant bacillus in sputum negative with GeneXpert analysis, antiphospholipid antibodies negative, and anticytoplasmic antibodies of neutrophilic polynuclear antibodies ANCA-PR3 positive to 63 UI/mL. Ear, nose, and throat examination showed a highly inflamed nasal mucosa, suggesting bacterial infection. The patient received antibiotic treatment, the examination also showed subglottic stenosis causing dysphonia. Ophthalmologic examination was indicative of bilateral episcleritis. Transthoracic ultrasound showed ischemic cardiomyopathy, which was complicated by a left intraventricular thrombus and a circumferential effusion with fibrin deposits. Other complementary tests, such as PET scan or biopsy (pulmonary, nasal, renal, retroperitoneal fibrosis), did not lead to suspicion of neoplastic pathology or therapeutic urgency. Based on these results, we diagnosed GPA with cardiovascular, pulmonary, renal, and nasal involvement associated with retroperitoneal fibrosis (Tables 2, 3). In addition to the anticoagulant [warfarin 2 mg with international normalized ratio (INR) of 2], the patient was treated with immunosuppressive therapy [bolus of methylprednisolone 15 mg/kg/day 3 days in a row, bolus of cyclophosphamide Endoxan 500 mg/m2 with Uromitexan (mesna) 500 mg/ m2), and oral corticosteroids (1 m/kg)], (Tables 4, 5), with clinical improvement including the disappearance of dyspnea and hemoptysis, radiological improvement including regression of excavated nodules (Fig. 6), decrease in the size of the periaortic infiltrate (Fig. 7), and a slight improvement in renal function (24-hour proteinuria of control at 0.7 mg/L) and ANCA levels (ANCA of control at 53 UI/mL) (Table 4). The follow-up was complicated by several relapses, hospitalization, and an increase of corticosteroid therapy
Table 1
The chronology of clinical signs
Time
Clinical presentation
T0
Bilateral jugular thrombosis
T1 1 month
Chest pain with productive cough bringing up hemoptoid sputum
T2 1 month and 1 week
Lumbago, dysphonia, epistaxis, deafness of the left ear
T3 1 month and 10 days
Red eyes and some purpuric lesions on the legs
Table 2
The diagnostic criteria in our patient
Diagnostic criteria
Arguments
Clinical
Lung: chest pain with hemoptoic sputum, bilateral nodular excavated lung lesions
Kidney: microscopic hematuria, positive urine sediment, 24-hour proteinuria
ENT: dysphonia, epistaxis, left ear deafness, subglottic stenosis on nasofibroscopy, perforation of the medial sinus wall
Ophthalmic: red eyes, bilateral episcleritis
Cardiovascular involvement: multiple thrombosis, circumferential pericardial effusion
Lumbar: lumbago, retroperitoneal fibrosis
Biology
Anticytoplasmic neutrophil antibodies ANCA-PR3 positive at 63 IU/mL
Histology
Biopsies not done because of the therapeutic emergency and the impossibility of stopping the anticoagulant treatment
ENT: Eyes, Nose, Throat; ANCA-PR3: anti-neutrophil cytoplasmic antibodies proteinase 3
Table 3
Diagnostic criteria
Diagnostic criteria granulomatosis with polyangiitis: should show two or more criteria
Nasal or oral inflammation
Abnormal thoracic X-ray
Active urinary sediment
Granulomatous inflammation in the biopsy
Table 4
Clinical course and follow-up visits
Time
Treatment administered
Clinical, biological, and radiological evolution
T0
A bolus of methylprednisolone 3 days in a row
Disappearance of purpuric lesions
T1 day 4
A first bolus of Endoxan + 60 mg prednisone
Disappearance of chest pain
Cessation of hemoptysis and epistaxis
T2 2 weeks
Second bolus of Endoxan + 60 mg prednisone
Regression of pulmonary nodules and periaortic infiltration
T3 2 weeks
3rd bolus of Endoxan + 60 mg prednisone
Decrease in cANCA
Decrease in 24-hour proteinuria
T4 3 weeks
Fourth bolus of Endoxan + 60 mg prednisone
Regression of jugular thrombosis
T5 3 weeks
Fifth bolus of Endoxan + 40 mg prednisone
Clinical, biological, radiological stability
T6 3 weeks
Sixth bolus of Endoxan + 40 mg prednisone
Clinical, biological, radiological stability
T7 1 week from the end of sixth bolus
Azathioprine 50 mg + 30 mg prednisone
Relapse leading to increase in corticotherapy
Table 5
Bolus of Endoxan and monitoring
Hour 0
Hour 1
Hour 2
Hour 3
Hour 4
Hour 5
500 saline serum (SS 0.9%)
Endoxan 1 g/500 cc of glycolic serum (GS 5%)
1/3 solution mesna (600 mg/ 100 cc GS 5%)
500 cc of SS 0.9%
Furosemide
40 mg intravenous
1/3 solution mesna (600 mg/100 cc GS 5%)
Drinking water
1/3 solution mesna (600 mg/100 cc GS 5%)
Drinking water
Monitoring
Hour 0
Hour 1
Hour 2
Hour 3
Hour 5
Hour 6
Hour 7
Blood pressure
120/60 mmHg
120/60 mmHg
130/70 mmHg
130/70 mmHg
120/60 mmHg
120/60 mmHg
120/60 mmHg
Respiratory frequency
16 breaths per minute
16 breaths per minute
17 breaths per minute
16 breaths per minute
16 breaths per minute
16 breaths per minute
16 breaths per minute
Pulse
63 beats per minute
70 beats per minute
73 beats per minute
75 beats per minute
70 beats per minute
65 beats per minute
65 beats per minute
Temperature
37 °C
37 °C
37 °C
37 °C
37 °C
37 °C
37 °C

Discussion

Granulomatosis with polyangiitis (Wegener's) is a necrotizing vasculitis combining inflammation of the vascular wall with peri- and extravascular granulomatosis [2]. Despite the discovery of anti-PR3 ANCAs that are highly specific for GPA, the pathogenesis of this disease is still poorly understood; however, neutrophils are the key players because they produce the autoantigen, proteinase 3, and their regulation is altered in patients [2]. Clinically, it is characterized in its full form by ENT signs and lung and kidney involvement. Other systemic manifestations may occur, and the risk of VTE is high [7]. Chest X-rays and CT scans show nodules, single or bilateral, single or multiple, excavated in half of the cases. Single or bilateral pulmonary infiltrates may also appear. Granulomatous pseudotumoral lung masses are possible [2, 6] (Table 1).
The presence of thrombosis in GPA is frequent. Analysis of a randomized controlled trial Wegener's Granulomatosis Etanercept Trial (WGET), which included patients with GPA, showed a VTE incidence of 7.0 per 100 person-years [4]. An increased likelihood of VTE was reported in a population-based incident AAV cohort, which was driven by a significantly increased risk of developing deep venous thrombosis (DVT) [7]. The analysis of a large cohort of patients with eosinophilic granulomatosis with polyangiitis (EGPA), GPA, and MPA demonstrated occurrence of VTEs in 8.2%, 8.0%, and 7.8% of patients, respectively [8]. In a prospective study, Merkel et al. [4] found an increased incidence of 7.0/100 person-years of VTE in Wegener granulomatosis (WG) patients. For comparison, in healthy Swedish men, the incidence is 0.3/100 person-years [9]. The cause of this increased incidence of VTE in WG patients cannot be derived from the study of Merkel et al. More recently, an analysis of data derived from several trials conducted by the European Vasculitis Society showed VTE occurrence in 41 (9.8%) of 417 patients with GPA or MPA [10]. Hansson et al. found an increased incidence of VTE just before and after the diagnosis of AAV of 1.8/100 person-years, compared with 0.3 in a healthy population of the same age [9]. The cause of the increased risk of VTE in AAV patients, especially when the disease is active, is unknown. Changes in endothelial function and hypercoagulability, especially during active disease, could explain this risk of VTE. Both cytokines and ischemia are known to cause endothelial damage [11]. Circulating ANCAs may also cause endothelial damage [12]. Increased platelet aggregation [11] and decreased fibrinolytic capacity [13] during active disease also appeared to cause thrombosis in AAV patients.
Retroperitoneal fibrosis (RPF) is very rare in granulomatosis with polyangiitis. The incidence of RPF is 0.1 per 100,000 population/year, with a prevalence of 1.4 per 100,000 population. Seventy percent of cases are idiopathic [14]. The remaining cases may be secondary to infections, abdominal surgery, medication, or malignant tumors. Recently, idiopathic retroperitoneal fibrosis was reported among the manifestations of immunoglobulin (Ig)G4 disease. This disease is responsible for only a portion of idiopathic retroperitoneal fibrosis cases (50%) [15, 16]. Imaging plays an important role in the diagnosis of RPF, in the distinction between benign and malignant forms, and finally in the monitoring of the evolution under treatment [14]. However, if diagnostic dilemmas exist and an underlying malignancy is suspected, or if there is no response to initial treatment, biopsy must be performed to confirm the diagnosis.
The association of retroperitoneal fibrosis with c-ANCA or p-ANCA positive systemic vasculitis is described in the literature, for granulomatosis with polyangiitis as well as in other vasculitides such as Churg–Strauss syndrome [17]. Revilla et al. reported a case of a 74-year-old man with a past infrarenal abdominal aortic aneurysm. Cavitating pulmonary nodules and retroperitoneal fibrosis with periaortic alterations were detected on computed tomography. Laboratory investigations revealed that the patient was positive for cytoplasmic antineutrophil cytoplasmic antibodies (c-ANCA), and necrotizing granulomas were observed on the lung lesion biopsies retroperitoneal tissue. The patient was diagnosed with GPA, and immunosuppressive therapy was prescribed with glucocorticoids 1 mg/kg for 3 days and methotrexate 20 mg per week, which led to a clinical and radiological improvement [2]. Izzedine et al. reported the case of a 51-year-old man with abdominal pain, urinary symptoms, and a constitutional syndrome. Imaging revealed retroperitoneal fibrosis. Necrotizing granulomas, giant cells, and a lympho-epithelioid cellular infiltrate were observed on the retroperitoneal tissue biopsy. The patient responded poorly to antituberculous treatment. Finally, a renal biopsy was performed, which revealed pauci-immune rapidly progressive glomerulonephritis with necrotizing vasculitis. Alveolar opacities compatible with alveolar hemorrhages were observed on thoracic CT, and a diagnosis of GPA was made. The patient showed significant improvement after treatment with immunosuppressive agents and corticosteroids [18].
These observations show that, if the clinical presentation is suggestive of vasculitis, the discovery of retroperitoneal fibrosis should not lead to further investigations and will be considered secondary to GPA. Immunosuppressive treatment must be started quickly given the rapid evolution of the disease and the functional and vital prognosis involved. Our observation confirms this notion. The diagnosis of RPF has been attributed to GPA; in this sense, the complementary examinations (PET scan and biopsy) in search of neoplasia or other etiology have not been realized. Our patient responded favorably to immunosuppressive therapy and corticosteroids. The similarly responding retroperitoneal lesion may suggest that this is an unusual presentation in GPA.

Conclusion

Granulomatosis with polyangiitis is a systemic, multiorgan disease with an increased risk of VTE; however, the association with retroperitoneal fibrosis remains rare, and systematic biopsy does not seem justified in the absence of clinical and/or paraclinical guidance.

Acknowledgments

Not applicable.

Declarations

Not applicable.
Written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.

Competing interests

The authors declare that they have no competing interests.
Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://​creativecommons.​org/​licenses/​by/​4.​0/​. The Creative Commons Public Domain Dedication waiver (http://​creativecommons.​org/​publicdomain/​zero/​1.​0/​) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Unsere Produktempfehlungen

e.Med Interdisziplinär

Kombi-Abonnement

Für Ihren Erfolg in Klinik und Praxis - Die beste Hilfe in Ihrem Arbeitsalltag

Mit e.Med Interdisziplinär erhalten Sie Zugang zu allen CME-Fortbildungen und Fachzeitschriften auf SpringerMedizin.de.

e.Med Allgemeinmedizin

Kombi-Abonnement

Mit e.Med Allgemeinmedizin erhalten Sie Zugang zu allen CME-Fortbildungen und Premium-Inhalten der allgemeinmedizinischen Zeitschriften, inklusive einer gedruckten Allgemeinmedizin-Zeitschrift Ihrer Wahl.

Literatur
1.
Zurück zum Zitat Jennette JC, Falk RJ, Bacon PA, Basu N, Cid MC, et al. Revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum. 2012;65(1):1–11.CrossRef Jennette JC, Falk RJ, Bacon PA, Basu N, Cid MC, et al. Revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum. 2012;65(1):1–11.CrossRef
2.
Zurück zum Zitat Revilla EMG, Fernandez AA, Ramirez MTR, Pardo SC, Moragues MAJ. Retroperitoneal fibrosis with periaortitis: a case report of an unusual form of presentation of granulomatosis with polyangiitis. Respir Med Case Rep. 2016; 121-4 Revilla EMG, Fernandez AA, Ramirez MTR, Pardo SC, Moragues MAJ. Retroperitoneal fibrosis with periaortitis: a case report of an unusual form of presentation of granulomatosis with polyangiitis. Respir Med Case Rep. 2016; 121-4
3.
Zurück zum Zitat Faurschou M, Mellemkjaer L, Sorensen IJ, Thomsen BS, Dreyer L, Baslund B. Increased morbidity from ischemic heart disease in patients with Wegener’s granulomatosis. Arthritis Rheum. 2009;60:1187–92.CrossRef Faurschou M, Mellemkjaer L, Sorensen IJ, Thomsen BS, Dreyer L, Baslund B. Increased morbidity from ischemic heart disease in patients with Wegener’s granulomatosis. Arthritis Rheum. 2009;60:1187–92.CrossRef
4.
Zurück zum Zitat Merkel PA, Lo GH, Holbrook JT, Tibbs AK, Allen NB, Davis JC Jr, et al. Brief communication: high incidence of venous thrombotic events among patients with Wegener granulomatosis: the Wegener’s Clinical Occurrence of Thrombosis (WeCLOT) Study. Ann Intern Med. 2005;142:620–6.CrossRef Merkel PA, Lo GH, Holbrook JT, Tibbs AK, Allen NB, Davis JC Jr, et al. Brief communication: high incidence of venous thrombotic events among patients with Wegener granulomatosis: the Wegener’s Clinical Occurrence of Thrombosis (WeCLOT) Study. Ann Intern Med. 2005;142:620–6.CrossRef
5.
Zurück zum Zitat Berti A. Risk of cardiovascular disease and venous thromboembolism among patients with incident ANCA-associated vasculitis: a 20 year population-based cohort study. Mayo Clin Proc. 2018;93(5):597–606.CrossRef Berti A. Risk of cardiovascular disease and venous thromboembolism among patients with incident ANCA-associated vasculitis: a 20 year population-based cohort study. Mayo Clin Proc. 2018;93(5):597–606.CrossRef
6.
Zurück zum Zitat Gibelin A, Maldini C, Mahr A. Epidemiology and etiology of Wegener granulomatosis, microscopic polyangiitis, Churg–Strauss syndrome, and Goodpasture syndrome: vasculitides with frequent lung involvement. Semin Respir Crit Care Med. 2011;32:264–73.CrossRef Gibelin A, Maldini C, Mahr A. Epidemiology and etiology of Wegener granulomatosis, microscopic polyangiitis, Churg–Strauss syndrome, and Goodpasture syndrome: vasculitides with frequent lung involvement. Semin Respir Crit Care Med. 2011;32:264–73.CrossRef
7.
Zurück zum Zitat Berti A, Matteson EL, Crowson CS, Specks U, Cornec D. Risk of cardiovascular disease and venous thromboembolism among patients with incident ANCA-associated vasculitis: a 20-year population-based cohort study. Mayo Clin Proc. 2018;93:597–606.CrossRef Berti A, Matteson EL, Crowson CS, Specks U, Cornec D. Risk of cardiovascular disease and venous thromboembolism among patients with incident ANCA-associated vasculitis: a 20-year population-based cohort study. Mayo Clin Proc. 2018;93:597–606.CrossRef
8.
Zurück zum Zitat Allenbach Y, Seror R, Pagnoux C, et al. High frequency of venous thromboembolic events in Churg–Strauss syndrome, Wegener’s granulomatosis and microscopic polyangiitis but not polyarteritis nodosa: a systematic retrospective study on 1130 patients. Ann Rheum Dis. 2009;68:564–7.CrossRef Allenbach Y, Seror R, Pagnoux C, et al. High frequency of venous thromboembolic events in Churg–Strauss syndrome, Wegener’s granulomatosis and microscopic polyangiitis but not polyarteritis nodosa: a systematic retrospective study on 1130 patients. Ann Rheum Dis. 2009;68:564–7.CrossRef
9.
Zurück zum Zitat Hansson PO, Welin L, Tibblin G, Eriksson H. Deep vein thrombosis and pulmonary embolism in the general population. ‘The Study of Men Born in 1913.’ Arch Intern Med. 1997;157:1665–70.CrossRef Hansson PO, Welin L, Tibblin G, Eriksson H. Deep vein thrombosis and pulmonary embolism in the general population. ‘The Study of Men Born in 1913.’ Arch Intern Med. 1997;157:1665–70.CrossRef
10.
Zurück zum Zitat Kronbichler A, Leierer J, Leierer G, Mayer G, Casian A, Höglund P, et al. Clinical associations with venous thromboembolism in anti-neutrophil cytoplasm antibody-associated vasculitides. Rheumatology (Oxford). 2017;56:704–8. Kronbichler A, Leierer J, Leierer G, Mayer G, Casian A, Höglund P, et al. Clinical associations with venous thromboembolism in anti-neutrophil cytoplasm antibody-associated vasculitides. Rheumatology (Oxford). 2017;56:704–8.
11.
Zurück zum Zitat Somer T. Thrombo-embolic and vascular complications in vasculitis syndromes. Eur Heart J. 1993;14:24–9.PubMed Somer T. Thrombo-embolic and vascular complications in vasculitis syndromes. Eur Heart J. 1993;14:24–9.PubMed
12.
Zurück zum Zitat Jennette JC, Xiao H, Falk RJ. Pathogenesis of vascular inflammation by antineutrophil cytoplasmic antibodies. J Am Soc Nephrol. 2006;17:1235–42.CrossRef Jennette JC, Xiao H, Falk RJ. Pathogenesis of vascular inflammation by antineutrophil cytoplasmic antibodies. J Am Soc Nephrol. 2006;17:1235–42.CrossRef
13.
Zurück zum Zitat Jordan JM, Allen NB, Pizzo SV. Defective release of tissue plasminogen activator in systemic and cutaneous vasculitis. Am J Med. 1987;82:397–400.CrossRef Jordan JM, Allen NB, Pizzo SV. Defective release of tissue plasminogen activator in systemic and cutaneous vasculitis. Am J Med. 1987;82:397–400.CrossRef
14.
Zurück zum Zitat Langford CA, Talar-Williams C, Sneller MC. Use of methotrexate and glucocorticoids in the treatment of Wegener’s granulomatosis. The long-term renal outcome in patients with glomerulonephritis. Arthritis Rheum. 2001;43:8. Langford CA, Talar-Williams C, Sneller MC. Use of methotrexate and glucocorticoids in the treatment of Wegener’s granulomatosis. The long-term renal outcome in patients with glomerulonephritis. Arthritis Rheum. 2001;43:8.
15.
Zurück zum Zitat Zen Y, Onodera M, Inoue D, et al. Retroperitoneal fibrosis: a clinicopathologic study with respect to immunoglobulin G4. Am J Surg Pathol. 2009;33:1833–9.CrossRef Zen Y, Onodera M, Inoue D, et al. Retroperitoneal fibrosis: a clinicopathologic study with respect to immunoglobulin G4. Am J Surg Pathol. 2009;33:1833–9.CrossRef
16.
Zurück zum Zitat Koo BS, Koh YW, Hong S, et al. Clinicopathologic characteristics of IgG4-related retroperitoneal fibrosis among patients initially diagnosed as having idiopathic retroperitoneal fibrosis. Mod Rheumatol. 2015;25:194–8.CrossRef Koo BS, Koh YW, Hong S, et al. Clinicopathologic characteristics of IgG4-related retroperitoneal fibrosis among patients initially diagnosed as having idiopathic retroperitoneal fibrosis. Mod Rheumatol. 2015;25:194–8.CrossRef
17.
Zurück zum Zitat Fujii K, Hidaka Y. Churg-strauss syndrome complicated by chronic periaortitis: a case report and review of the literature. Intern Med. 2012;51:109–12.CrossRef Fujii K, Hidaka Y. Churg-strauss syndrome complicated by chronic periaortitis: a case report and review of the literature. Intern Med. 2012;51:109–12.CrossRef
18.
Zurück zum Zitat Izzedine H, Servais A, Launay-Vacher V, Deray G. Retroperitoneal fibrosis due to Wegener’s granulomatosis: a misdiagnosis as tuberculosis. Am J Med. 2002;113:164–6.CrossRef Izzedine H, Servais A, Launay-Vacher V, Deray G. Retroperitoneal fibrosis due to Wegener’s granulomatosis: a misdiagnosis as tuberculosis. Am J Med. 2002;113:164–6.CrossRef
Metadaten
Titel
Vascular thromboses with retroperitoneal fibrosis: a case report
verfasst von
Hanane Charaf
Rachida Zahraoui
Mouna Soualhi
Nezha Rguig
Jamal Eddine Bourkadi
Daoud Ali Mohamed
Nasser Ittimad
Publikationsdatum
01.12.2022
Verlag
BioMed Central
Erschienen in
Journal of Medical Case Reports / Ausgabe 1/2022
Elektronische ISSN: 1752-1947
DOI
https://doi.org/10.1186/s13256-021-03235-0

Weitere Artikel der Ausgabe 1/2022

Journal of Medical Case Reports 1/2022 Zur Ausgabe